Mild Cognitive Impairment (MCI): Is It Dementia?

Mild cognitive impairment — MCI — is a specific clinical category that sits between normal cognitive aging and dementia. It is not a minor version of dementia, and it is not simply "getting older." It is a defined diagnostic territory with its own criteria, prognosis, and management. For many people, MCI is the stage at which a cognitive concern first becomes a medical concern.

If you or a family member has been told by a clinician that the diagnosis is MCI, this article explains what that actually means, what happens next, and why some people with MCI progress to dementia and others do not.

What MCI is

The formal clinical definition of MCI includes:

• Cognitive decline — measurable, and greater than expected for age and education.
• Preserved daily function — the person is still generally independent. Complex tasks may be harder, but activities of daily living (dressing, bathing, eating, basic self-care) are intact.
• Not dementia — specifically, the cognitive changes do not interfere substantially with work or social function.

MCI is most commonly diagnosed when someone reports a concern, a family member corroborates it, and formal testing shows a measurable decline in one or more cognitive domains — usually memory.

Subtypes

Clinicians divide MCI into subtypes based on which cognitive domains are affected:

• Amnestic MCI — memory is the main problem. This is the subtype most associated with eventual progression to Alzheimer's disease.
• Non-amnestic MCI — the main problem is in another domain (language, visuospatial, executive function). This subtype is more often associated with progression to non-Alzheimer dementias like Lewy body, vascular, or frontotemporal dementia.
• Single-domain vs multi-domain — whether one or several cognitive areas are affected.

The subtype matters for prognosis and for specialist evaluation decisions, though in a primary care setting the distinction is less important than simply identifying that a measurable change has occurred.

How MCI is diagnosed

A typical evaluation includes:

1. Detailed history from the patient and a family member.
2. Focused cognitive testing — longer than a brief screen. The MoCA is often used, or a full neuropsychological battery if available.
3. Medical workup to rule out reversible causes — thyroid function, B12, folate, medication review, sleep evaluation, depression screening.
4. Brain imaging — MRI, sometimes looking for patterns of atrophy or vascular changes.
5. Functional assessment — usually via an interview that confirms daily activities are preserved.

Brief screens like the Mini-Cog or clock drawing test often flag MCI, but the diagnosis itself typically requires longer testing because MCI is a relatively subtle finding.

Risk of progression to dementia

Not everyone with MCI progresses to dementia. The numbers from published longitudinal studies vary, but a reasonable central estimate:

• Roughly 10 to 15 percent of people with MCI progress to dementia each year.
• Over five years, roughly half of people with amnestic MCI progress.
• A significant minority remain stable for many years.
• A small group — particularly those whose MCI was driven by depression, medication effects, or sleep problems — actually revert to normal cognition with treatment of the underlying cause.

The wide variation is partly why MCI is both a useful category and a frustrating diagnosis. It names the territory without predicting the outcome.

What increases progression risk

Factors associated with higher risk of progression to dementia:

• Amnestic subtype (memory-predominant)
• Multi-domain involvement
• APOE ε4 carrier status — a genetic risk factor for Alzheimer's disease
• Vascular risk factors — hypertension, diabetes, smoking, high cholesterol
• Poor sleep, including untreated sleep apnea
• Depression and social isolation
• Low physical activity

What reduces progression risk (or at least may)

The strongest evidence exists for a handful of interventions:

• Controlling vascular risk factors. Blood pressure, diabetes, and cholesterol management reduce both vascular dementia and mixed dementia risk.
• Physical activity. Aerobic exercise has the most consistent data. 150 minutes of moderate activity per week is the common recommendation.
• Treating sleep apnea. Untreated sleep apnea is associated with accelerated cognitive decline.
• Addressing hearing loss. The 2020 Lancet Commission on dementia prevention identified untreated hearing loss as one of the largest modifiable risk factors. Hearing aids appear to slow decline in people with MCI and hearing loss.
• Social engagement. Loneliness and social isolation are associated with faster progression.
• Treating depression. Depression can both mimic MCI and accelerate it.
• Nutrition. The Mediterranean and MIND diets have the best observational evidence, though not the strongest randomized-trial evidence.
• Cognitive engagement. Reading, puzzles, learning new skills — "cognitive reserve" is real, though the mechanisms are debated.

None of these guarantee anything. All of them are reasonable regardless of MCI status.

What about medications?

For MCI specifically, the medication landscape is narrower than for established dementia:

• Cholinesterase inhibitors (donepezil, rivastigmine) are sometimes prescribed off-label for MCI, particularly amnestic subtype. Evidence for slowing progression is mixed; benefits, if any, are modest.
• Amyloid-targeting therapies (lecanemab, donanemab) are now approved for early Alzheimer's disease, which includes MCI with amyloid-positive biomarkers. These are specialist-prescribed, require specific testing to identify candidates, carry real risks (including brain swelling and bleeding), and demand careful monitoring.
• Memantine is used in moderate-to-severe Alzheimer's disease, not typically in MCI.

A specialist — neurologist or geriatric psychiatrist — is the right person to discuss whether medication makes sense in a specific case.

Living with MCI

A diagnosis of MCI is often more emotionally difficult than dementia because of the uncertainty. Some practical things that help:

• Maintain a baseline record. Keep brief cognitive screens — the clock drawing test is suitable — done a few times a year. Trend over time is more informative than any single result.
• Annual or semi-annual follow-up with the diagnosing clinician. Changes are often gradual and may be missed in shorter intervals.
• Early legal and financial planning, while capacity is clearly preserved.
• Have the conversation with family early. Discussing driving, finances, and future care is easier while it's a hypothetical.
• Take lifestyle interventions seriously. The modifiable risk factors above have the best evidence for slowing decline, and the time to apply them is now, not after progression.

What to ask your doctor

• What subtype of MCI do you think this is?
• What did the testing show specifically? Are there memory deficits, executive function deficits, or both?
• Should we do biomarker testing — amyloid PET or cerebrospinal fluid — to clarify whether this is early Alzheimer's disease?
• What are my modifiable risk factors?
• What should we track? How often should we re-test?
• Should I see a specialist?

Related reading

• Dementia vs Alzheimer's: What's the Difference?
• Early Signs of Dementia vs Normal Aging
• MMSE vs Clock Drawing Test vs MoCA
• Sleep and Dementia Risk

References

• Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018;90(3):126–135.
• Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413–446.
• Alzheimer's Association. Mild Cognitive Impairment. alz.org.

---

Disclosure: Dr. Shimada is the founder of Tokei Health. This article is informational and is not a substitute for individual medical advice from your own clinician.